Cargando…

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes

Two Janus‐associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate‐risk and high‐risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mascarenhas, John O., Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324085/
https://www.ncbi.nlm.nih.gov/pubmed/35385124
http://dx.doi.org/10.1002/cncr.34222